

Please amend page 20, line 1 as follows:

Claims What is claimed is:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A process for the production of an ^{18}F -labelled tracer which comprises treatment of a solid support-bound precursor of formula (I):




wherein the TRACER is of formula (A):



or an amine protected derivative thereof, wherein Y^- is an anion, preferably trifluoromethylsulphonate (triflate) anion; and

R^1 is either (i) a group $\text{CH-NP}^{1\text{A}}\text{P}^{2\text{A}}$ in which $\text{P}^{1\text{A}}$ and $\text{P}^{2\text{A}}$ are each independently hydrogen or a protecting group, or (ii) a carbonyl group;

with $^{18}\text{F}^-$ to produce the labelled tracer of formula (II)




or an amine protected derivative thereof, wherein R^1 is as defined for the compound of formula (I);

optionally followed by:


- (i) removal of excess $^{18}\text{F}^-$, for example by ion-exchange chromatography; and/or
- (ii) removal of any protecting groups; and/or
- (iii) removal of organic solvent; and/or
- (iv) formulation of the resultant compound of formula (II) as an aqueous solution.

2. (Original) A process according to claim 1 for the production of $5[^{18}\text{F}]$ fluorouracil which comprises treatment of a solid support-bound precursor of formula (Ia):



or an amine protected derivative thereof, wherein Y^- is an anion, preferably trifluoromethylsulphonate (triflate) anion;


with $^{18}\text{F}^-$ to produce the labelled tracer of formula (IIa)



or an amine protected derivative thereof, optionally followed by:


- (i) removal of excess $^{18}\text{F}^-$, for example by ion-exchange chromatography; and/or
- (ii) removal of organic solvent; and/or
- (iii) removal of any protecting groups; and/or
- (iv) formulation of the resultant compound of formula (IIa) as an aqueous solution.

3. (Original) A process according to claim 1 for the production of 5[¹⁸F]fluorocytosine which comprises treatment of a solid support-bound precursor of formula (Ib):



or an amine protected derivative thereof, wherein Y⁻ is an anion, preferably trifluoromethylsulphonate (triflate) anion, P^{1A} and P^{2A} are independently hydrogen or a protecting group;


with ¹⁸F⁻ to produce the labelled tracer of formula (IIb)





or an amine protected derivative thereof, wherein P^{1A} and P^{2A} are as defined for the compound of formula (Ib), optionally followed by:

- (i) removal of excess ¹⁸F⁻, for example by ion-exchange chromatography; and/or
- (ii) removal of organic solvent; and/or
- (iii) removal of any protecting groups; and/or
- (iv) formulation of the resultant compound of formula (IIb) as an aqueous solution.

4. (Currently amended) A process for the production of an ¹⁸F-labelled tracer which comprises treatment of a compound of formula (III), (IIIa), or (IIIb):





or an amine protected derivative thereof, wherein R^1 , P^{2A} , P^{1A} , and Y^- are as defined in claim 1, and phenyl ring B is optionally substituted with one to five substituents independently selected from halo, C_{1-6} alkyl, C_{1-6} haloalkyl, hydroxy, C_{1-6} alkoxy, amino, C_{1-6} hydroxyalkyl, and nitro; with $^{18}F^-$ to produce the labelled tracer of formula (II), (IIa), or (IIb) respectively as defined in claims 1 to 3 or an amine protected derivative thereof, optionally followed by:


- (i) removal of excess $^{18}F^-$, for example by ion-exchange chromatography; and/or
- (ii) removal of any protecting groups; and/or
- (iii) removal of organic solvent; and/or
- (iv) formulation of the resultant compound of formula (II), (IIa), or (IIb) as an aqueous solution.

5. (Currently amended) A process for the production of a ^{18}F -labelled tracer of formula (II), ~~(IIa), or (IIb)~~ according to ~~any one of claims 1 to 4~~ claim 1, for use in PET.

6. (Original) A compound of formula (I):




wherein the TRACER is of formula (A):



or an amine protected derivative thereof, wherein Y^- is an anion, preferably trifluoromethylsulphonate (triflate) anion; and


R^1 is either (i) a group $CH-NP^{1A}P^{2A}$ in which P^{1A} and P^{2A} are each independently hydrogen or a protecting group, or (ii) a carbonyl group.

7. (Original) A compound of formula (Ia):



or an amine protected derivative thereof, wherein Y^- is an anion, preferably trifluoromethylsulphonate (triflate) anion.

8. (Original) A compound of formula (Ib):



or an amine protected derivative thereof, wherein Y^- is an anion, preferably trifluoromethylsulphonate (triflate) anion, P^{1A} and P^{2A} are independently hydrogen or a protecting group.

9. (Currently amended) A radiopharmaceutical kit for the preparation of an ^{18}F -labelled tracer for use in PET, which comprises:

- (i) a vessel containing a compound of formula (I), ~~(Ia), or (Ib)~~ as defined in ~~any one of claims 1 to 3 claim 1, or a compound of formula (III), (IIIa), or (IIIb) as defined in claim~~ [4] or an amine protected derivative thereof; and
- (ii) means for eluting the vessel with a source of $^{18}\text{F}^-$;
- (iii) an ion-exchange cartridge for removal of excess $^{18}\text{F}^-$; and optionally
- (iv) a cartridge for solid-phase deprotection of the resultant product of formula (II), ~~(IIa), or (IIb)~~, as defined in ~~any one of claims 1 to 3 claim 1~~.

10. (Currently amended) A cartridge for a radiopharmaceutical kit for the preparation of an ^{18}F -labelled tracer for use in PET which comprises:

- (i) a vessel containing a compound of formula (I), ~~(Ia), or (Ib)~~ as defined in ~~any one of claims 1 to 3 claim 1, [or a compound of formula (III), (IIIa), or (IIIb) as defined in claim 4]~~ or an amine protected derivative thereof; and
- (ii) means for eluting the vessel with a source of $^{18}\text{F}^-$.

11. (Currently amended) A method for obtaining a diagnostic PET image which comprises the step of using a radiopharmaceutical kit according to claim 9 ~~or a cartridge for a radiopharmaceutical kit according to claim 10~~.

12. (New) A method for obtaining a diagnostic PET image which comprises the step of using a cartridge for a radiopharmaceutical kit according to claim 10.